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Abstract
Background: Risk of encephalitis from West Nile virus (WNV) infection increases dramatically with age. Understanding the
basis of this susceptibility requires development of suitable animal models. Here, we investigated the immune response to
WNV in old non-human primates.
Methodology/Principal Findings: We investigated clinical, immunological and virological correlates of WNV infection in
aging non-human primates. Aged (17–30yrs) and adult (6–9yrs) Rhesus macaques (RM) were challenged with WNV in the
presence or the absence of the mosquito salivary gland extract (SGE) to approximate natural infection. None of the 26
animals exhibited clinical signs of the disease. Quantitative PCR suggested discrete and short-lived viremia, but infectious
virus was never isolated. There was markedly increased, age-independent, proliferation of CD3
2 non-B cells, followed by B-
cell proliferation, which correlated to the loss of detectable WNV genomes. Moreover, animals primed with mosquito
salivary gland extract exhibited reduced circulating WNV RNA. While we found the expected age-associated reduction in T
cell proliferation, adaptive immunity did not correlate with infection outcome. That was further confirmed in a cohort of
thymectomized and/or CD8 T-cell depleted Cynomolgus macaques (CM; N=15), who also failed to develop WNV disease.
Conclusions/significance: Results are consistent with strong and age-independent innate resistance of macaques against
WNV challenge. This animal model is therefore not suitable for vaccine and therapeutic testing against WNV. However,
understanding the basis of their innate resistance against WNV in macaques could provide helpful clues to improve anti-
WNV protection of older adults.
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Introduction
West Nile virus (WNV) is a positive stranded RNA flavivirus,
naturally transmitted in an enzootic cycle between mosquitoes and
birds, which can readily infect a wide variety of dead-end hosts,
including humans. It belongs to the Japanese encephalitis virus
serocomplex of flaviviruses and causes human meningitic/
encephalitic disease of varying severity.
WNV strain 1 clade a (1a) first entered the United States in
Queens, NY, in 1999 spreading throughout the US by 2004 and
providing an excellent example of a present day emerging
pathogen. From 2004 to 2007 alone, CDC has registered
.7800 cases of fever and .5000 cases of encephalitis in the
US, with an approximate fatality rate of 10% following onset of
encephalitis (www.cdc.gov/ncidod/dvbid/westnile/).
While 80% adults under the age of 50 experience no symptoms
upon WNV infection, and only 1 in 150 experience severe disease
with meningitis/encephalitis [1,2], the situation is much more dire
withadvanced age.Lethalityincreases10-foldinpeopleover50and
then to 40-50-fold at age 70, with a fatality rate of over 20% [3].
Despite intense efforts [4,5] to date there is no approved human
WNV vaccine. Treatment options remain partially effective, and
recent reports suggest that current treatments may have no
significant impact upon length of hospitalization [6]. Furthermore,
the elderly are at greater risk of long term neurological defects from
WNV infection, including chronic neurologic issues such as limb
numbness or partial paralysis. Therefore, it is critical to understand
protective immunity in adults and its decline in aging to devise
appropriate vaccination strategies and immunomodulatory treat-
ments to protect older adults against WNV [7].
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of susceptibility, persistence and resistance to strain 1a WNV [5,8].
We showed in the mouse model that viral titers in the brains, but
not in the blood and visceral organs, strictly correlated with
mortality; WNV entered the brains of old and adult animals alike,
but whereas most adult animals controlled neurovirulence, most
old animals failed to do so [9]. This was due to profound defects in
the development of antiviral effector CD4 and CD8 T cell
response in old mice [9].
Rodent studies, however, do not always yield results that
translate into humans, including failure in humans of vaccine
approaches that were successful in mice [10]. Therefore,
validation of immunological results in a non-human primate
model is highly desirable. Prior work with adult Rhesus macaque
(RM) exposed to infection with 10
5 plaque-forming units (pfu)
WNV found measurable viremia and humoral response, but no
deaths nor clinical symptoms [11]. Another study found a clearly
developed humoral response and a similar lack of clinical
symptoms in baboons [12]. Finally, a natural outbreak of WNV
at the Tulane NPRC, with over 700 animals exposed to WNV,
also failed to reveal clinical symptoms or mortality [13]. One
confounding issue in that study was the endemic exposure to
flaviviruses in the area, which could not be controlled for in the
natural experiment. To date, only direct intracranial infection of
RM resulted in clinical presentation of WNV encephalitis [14] in
non-human primates. As mentioned, the immunocompromised
and the elderly have significantly increased risk of severe disease
[1] associated pathology [15], and death. We therefore revisited
the monkey model attempting to mirror natural human infection
and included animals between 17–30 years of age (corresponding
to 51–90 yrs in humans [16]) as well as immunodeficient animals,
none of which were used in prior studies. We also included
priming of the animals with mosquito salivary gland extracts
(SGE), because recent mouse studies showed that this ‘‘natural’’
pretreatment may increase susceptibility to WNV [17]. Here we
present our findings from several cohorts of adult, middle-aged
and old RM and Cynomolgus (CM) macaques (n=40), and
conclude that macaques exhibit strong and age-independent
resistance to this virus, that CD8 T cells are not required for
protection and that resolution of infection likely involves robust
innate immune mechanisms.
Results
Hypotheses, animal cohorts, dose and route of viral
challenge
We tested three major hypotheses in this study: (1) That in aged
animals, increasing the viral inoculum (based on prior studies)
and/or altering the route of administration would produce
neuroinvasion and clinical WNV disease (Cohorts 1 and 2); (2)
That priming with mosquito salivary gland extract (SGE) prior
and/or at the time of infection will increase susceptibility to
infection (Cohorts 3, 4 and 5); and (3) That deficiency in cellular
immunity will increase susceptibility of NHP to WNV disease
(Cohort 5).
Cohorts 1 and 3–5 received 10
7 pfu WNV, whereas cohort 2
received 10
9 pfu WNV, as described in Table 1: Cohorts 1, 4
and 5 received the inoculum s.c., whereas cohorts 2 and 3
received a split injection of WNV i.v. and s.c. (80%:20% and
66%:34%, for cohorts 2 and 3, respectively). The rationale for
split i.v. and s.c. route of infection was to mirror the natural
mosquito feeding mechanism, where the mosquito probes and
targets the capillary bed, while also depositing some of the virus,
along with saliva, subcutaneously. For cohorts 1 and 2, a total of
5/7 aged and 3/5 adult animals were implanted with real time
telemetry. Animals in cohorts 3–5 all received, in addition to the
virus, the mosquito SGE, to mimic more closely natural
infection, and also in the hope to produce a more pronounced
clinical infection, as suggested by the results of SGE adminis-
tration in rodents [17]. Cohort 3 (4 aged, 1 adult) and 4 (5 aged
and 2 adult RM), with a total of 12 animals, were each primed
with mosquito salivary gland extracts (SGE) prior to infection
Table 1. Rhesus macaque and Cynomolgus macaque cohorts.
Rhesus macaque cohorts
Cohort
Adults (6–10) 7.6yr
ave (age)
Aged(.17yrs) 21.5yr
ave (age) Total N WNV dose
Priming with SGE
(Aedes albopictus)
Route of
administration
Male Female Male Female
12 (8,8) 1 (6) 2(22,18) 3(20,19,18) 8 1610(7) pfu/animal N/A subcutaneous
22 (8,8) 1(10) 2(20,18) 5 1610(9) pfu/animal N/A IV/subcutaneos
(2 ml IV/500 ulSC)
31 (6) 1(20) 3(30,21,20) 5 1610(7) pfu/animal Primed w/1 SGE at d-60, boosted
at d-28, infected w/1 SGE at D0
IV/subcutaneous
(1 mlIV/500 ulSC)
42 (8,6) 2(25,20) 3(30,23,20) 7 1610(7) pfu/animal Primed w/1 SGE at d-60, boosted
at d-28, infected w/1 SGE at D0
subcutaneous
Cynomolgus macaque cohorts
Cohort Sham Thymectomized N WNV dose
Priming with SGE
(Aedes aegypti)
Route of
administration
Not depleted
(age)
DCD8
(age)
Not depleted
(age)
DCD8
(age)
54 (14,13,
13,13)
3 (18,15,
13)
4 (15,13,
13,11)
4 (15,13,
13,11)
15 1610(7)
pfu/animal
Primed twice a week w/1SGE
final prime was at d(2)14
infect w/2 SGE at D0
subcutaneous
doi:10.1371/journal.pone.0015514.t001
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monkeys with real time telemetry. Cohort 5 was set to test the
effects of CD8 depletion with or without thymectomy (induced
CD8 T-cell deficiency) upon resistance against WNV. This
cohort contained 15 CM; 3 were CD8 depleted, 4 were
thymectomized, 4 were thymectomized and CD8 depleted and
the remaining 4 served as control animals. All were primed with
SGE prior to s.c. infection and 9/15 were implanted with
telemetry devices (Tab. 1).
Macaques exhibit no clinical symptoms directly
attributable to WNV infection
All cohorts experienced changes in appetite and behavior
during the acute phase post infection up to d14; however, due to
the intense tissue sampling protocol these alterations could not
definitively be ascribed to WNV infection. All cohorts maintained
normal diurnal temperature rhythms (not shown). Two CM
(Cohort 5) developed fever at day 7, coincident with elevated white
cell counts, however, viremia was undetectable, and it was not
possible to relate the fever with viral infection. Both resolved the
fever and neither developed neurologic symptoms. In Cohort 5, 4/
15 CM developed a localized rash at the site of administration of
SGE, two of which subsequently developed a disseminated rash on
their abdomen, inner arms and legs. This was concurrent with
eosinophilia and likely represented an allergic reaction against
mosquito saliva. Most importantly, no animals in any of the
cohorts exhibited WNV-related neurological symptoms, regardless
of age.
Increased viral dose, intravenous route of infection and
SGE priming correlate to reduced duration and levels of
circulating viral RNA and the absence of viral shedding
Cohort 1 (1610
7 PFU/animal s.c.) exhibited surprisingly late
presence of viral loads, from d14 until at least d45, peaking at day
21 (Figure 1A-Blood). There were no significant differences in
viral titers or kinetics between the aged and adult animals (closed
vs. open boxes). Cohort 2 (Figure 1B-Blood) received 100-fold
higher WNV dose i.v. and s.c. Surprisingly, these animals had
shown very brief presence of circulating viral genomes in all
animals on d1 but disappearing by d4, and being significantly
higher in the adult animals on d1. RM groups primed with SGE
(Cohorts 3–5) also exhibited markedly decreased viral genome
loads (Figure 1C–E), and also only between days 1–4. Although
the peak levels of viral genomes observed in some animals were as
high as 10
5 genome equivalents/mgR N A ,w ew e r eu n a b l et o
culture WNV from plasma or whole blood in any of the animals
in this study. In Cohort 1 and 2 each animal had detectable
WNV RNA at some point (Cohort 1=8/8; cohort 2 =4/4). In
cohort 3, 4 and 5, 2/5, 2/7 and 12/15 animals had detectable
WNV RNA, respectively This, together with lack of any clinical
symptoms in any of the animals suggests that even when viral
RNA was detected in the blood, its infectivity was greatly
reduced.
We also evaluated viral shedding by examining urine (collected
via cytesis, immediately stabilized in tri-reagent or flash frozen)
from each cohort. We found detectable WNV RNA in cohort 1,
where it appeared on day 14 and 21 in all 8 animals and was
present at day 100 in 7 animals (Figure 1A-Urine). Again, we were
unable to culture WNV even from the urine of animals exhibiting
the highest levels of viral genomes. The viral genomes were
detected by at least replicate assays, in both RNA stabilized and in
flash frozen specimens, suggesting that detection was not an
artifact linked to the method of sample preservation. No viral
RNA was detected in the urine of any other cohort, suggesting that
SGE presence (cohorts 3–5) as well as i.v. inoculation (cohorts 2 &
3) and/or higher viral dose (cohort 2) may stimulate earlier and
more thorough viral clearance.
Proliferation of leukocytes in RM upon WNV infection
To characterize the immune response we investigated cellular
phenotype and proliferation in PBMC from Cohorts 1 and 2.
Proliferation was measured using Ki67, an intracellular marker
which labels cells that traversed the S-phase of the cell cycle (past
2–3 days) in combination with various cell surface markers to
identify T cells (CD3+) and B cells (CD3-, CD20+, HLA-DR+).
Proliferating non-T cells (Ki-67
+, CD3
2) made up less than 20%
(Figure 2A–B) pre-infection, but showed peak of proliferation
between 30–40%, on Day 7 in both cohorts. Panels C and D
illustrate the CD3
2 cell proliferation kinetics for each animal over
time in cohort 1 and 2 respectively. All animals exhibited marked
proliferation of the non-T cell pool at day 7. Of note, no animals
in Cohort 2 had detectable blood viral RNA at these time points
(Day 4, 7, 10). We next sought to positively identify and examine
proliferation of B cells. Figure 3A and B illustrates the gating
strategy used to identify proliferation (Ki67
+CD3
2CD20
+HLA-
DR
+) and frequency of B cells in Cohorts 1 and 2. B cell
proliferated strongly in both cohorts but with a slightly later onset
(d14 vs d10 Fig. 3C–D) and shorter duration in cohort 1;
proliferation in both cohorts declined by day 21 (Figure 3C–D).
Thus, B cells were responsible for d10–14 peak proliferation, but
not for the d7 proliferation burst found in the CD3- population.
There were no age-related differences in the extent of either non-
B, CD3- or of the B-cell proliferation. Identity of the major
proliferating day 7 cell population remains under investigation.
Aged and adult macaques produce robust anti-WNV IgM
and IgG antibody response
To assess whether B-cell proliferation was accompanied by
production of protective antibodies, we measured total IgM and
IgG anti-WNV Ab by ELISA, as well as their ability to inhibit
hemagglutination (HI). Again, we observed no difference in Ab
responses between old and adult animals. The majority of animals
from cohort 1 made anti-WNV IgM antibody by d14, with a
decline around d45, but often exhibited a second and persisting
wave of IgM (Figure 4). Generally, IgG antibodies began to
develop between d14 and 21 and persisted through the duration of
the study. IgM was also detected in the CSF of 3 animals (1 old -
17533) and 2 adults - 20027, 21148), either on d14 (17533), d28
(20027) or both (21148). In cohort 2, high dose infection (10
9 pfu/
i.v. and s.c.) was followed by an early rise in hemaglutinating
antibody on d10, with a peak on d21 and a decline by d60 (not
shown). Cohorts 3 and 4, primed with SGE (not shown) showed
Ab production beginning on d14, and with all but one animal
peaking by d28 and a decline by d60. Of note, the majority of
animals in Cohort 1 (lower dose, s.c.), maintained their peak titer
until d60, which correlated with prolonged circulating WNV RNA
and its sporadic shedding. By contrast, animals primed with
mosquito SGE (cohorts 3, 4 and 5) exhibited overall lower Ab
titers, consistent with absent or barely detectable and transient
WNV RNA. Fourteen of the fifteen animals from cohort 5 had
measurable HI titers [18] on d30 or 60 post infection (not shown).
Aged macaques exhibit delayed T-cell proliferative
response to WNV infection adults
T cell proliferation (Figure 5) in the 4 animals from Cohort 2
provided additional important clues into the host-pathogen interac-
Aged Monkeys Resist WNV Challenge
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from old animals (open symbols with dotted lines) proliferate in
response to WNV with delayed kinetics compared to adult RM,
reminiscent of the results reported by Li et al. in a mouse tumor
model [19]. However, this altered kinetic did not impact upon
clinical disease, as no animals exhibited signs of WNV disease. All
animals in this cohort displayed a prominent decrease in CD4+
proliferationonday4,immediatelypriortoinitiatingtheproliferative
burst at about day 7. It is tempting to speculate that this is due to the
withdrawal of all Ag-specific T-cells into the secondary lymphoid
organs in the course of initial priming [20], however, additional
experimentation is needed to address this issue conclusively.
Lack of CD8 T-cells does not impair macaque resistance
to WNV
Cohort 5 animal groups underwent thymectomy or CD8
depletion or both; the profound CD8 depletion in these animals is
Figure 2. Proliferation of CD3- cells post WNV infection. The 4 panels illustrate kinetics of proliferation based upon levels of Ki67 measured in
the total peripheral mononuclear cell population (PBMC) for cohort 1 and 2. Panels A and B illustrate proliferation of CD3 (2), non T cells, in cohort 1
and 2 respectively prior to infection through day 21. Each animal is represented by a dot (solid – adult; open - old). The center bar represents the
mean. Panels C and D illustrate proliferation of CD3(2) cells within the total PBMC population for each animal. Dashed lines illustrate the aged
animals solid lines illustrate the adult animals. All animals had increased proliferation of CD3(2), non-T cells, which peak by day 7 or 10 and then
decline. Asterisks illustrate significant change (p.0.05).
doi:10.1371/journal.pone.0015514.g002
Figure 1. Increase of Viral Dose and Addition of Mosquito Salivary Gland Extracts (SGE) Decrease circulating Viral RNA. Quantitative
PCR from each of the 5 cohorts as detected in Blood and Urine. Box plots illustrate maximum and minimum from each group. Bar illustrates
population median. Red dashed line illustrates assay limit of detection. Blood Column titled Blood Panel A cohort 1, panel B cohort 2, animals primed
with mosquito salivary gland extracts prior to infection are illustrated in Panel C cohort 3, panel D cohort 4, and panel E cohort 5. Column titled Urine
Panel A and B illustrate the transient virurea detected only in cohort 1 (panel A), the cohort 2 had no detectable virus in the urine even though we
examined time points as early as 5 hrs after IV infection.
doi:10.1371/journal.pone.0015514.g001
Aged Monkeys Resist WNV Challenge
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15514Figure 3. B cells Proliferate in Response to WNV Infection. Panel A and B: Representative profiles from flow cytometric analysis of PBMC from
animals in Cohort 1 and Cohort 2 prior to and at day 10 post WNV infection. The first panel illustrates the physical size and cellular granularity
(forward side scatter profile) of the PBMC. The next series of panels illustrate the sub populations defined first by expression of CD20 (to define B
cells) and CD3 status (T cells vs non-T cells). The next series illustrates the proliferation (Ki67+) within the B cells (CD3- CD20+ HLA-DR+). The final
calculations are expressed as percentages based upon the CD3- population for the B cells. Panel B illustrates the differences in B cell proliferation
found in Group 1 vs. Group 2 at d10 post infection. Lower panels (C and D) illustrate B cell proliferation (CD3-CD20+HLA/DR+ based upon levels of
Ki67 measured within the total CD3- populations for cohort 1 and 2. Panels C and D illustrate proliferation of Ki67+CD20+ cells in cohorts 1 and 2
respectively,. Dark lines illustrate the aged animals lighter lines illustrate the adult animals.
doi:10.1371/journal.pone.0015514.g003
Aged Monkeys Resist WNV Challenge
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neurological symptoms attributable to WNV infection. Viral load,
as determined by qPCR in all the animals in this cohort was just
above, but not significantly different from, baseline (via T test and
Fishers exact test) (Figure 1E). Of note, all of these animals were
primed with SGE prior to and at the time of infection and many of
them displayed elevated eosinophiles. Clinical eosinophilia in some
animals began 7 days after priming and continued after WNV
infection. Levels of eosinophiles ranged from 1.2% (0.08610
3/ul)
to 11.6% (0.83610
3/ul) [normal range 0–5% (0.0 to 0.4610
3/ul)]
and varied from animal to animal regardless of their adaptive
immune status (thymectomy or CD8 depletion). It is highly likely
that this eosinophilia reflects reaction to SGE, and that reaction
may well correlate with the rapid clearance of the virus, although
mediators of this clearance remain to be identified.
Discussion
In this study, we evaluated the effects of age, viral inoculum,
route of infection, mosquito factors and immunocompetency on
immunity against the WNV in the non-human primate model. We
were unable to detect any clinical signs of the disease, despite the
very advanced age of some of the animals, the use of CD8-
depleted animals, and the very high dose of the virus inoculated.
We confirmed prior reports that adult monkeys do not present
with symptomatic WNV infection. More importantly, we here
show that both aged and CD8-deficient non-human primates also
resolve viral infection and fail to exhibit clinical symptoms of
WNV disease when infected in a manner similar to the natural
course of infection with a high dose of the virus. All animals
displayed clear signs of contact with the virus, with measurable but
quickly disappearing viral RNA, and/or by developing and
maintaining humoral immune responses. In humans, only about
20% individuals develop symptoms, and 1:150 ends up with
severe, potentially fatal, encephalitis. The incidence of encepha-
litis, however, rises to 10% and higher in humans over 65 [1]. One
of the significant limitations in our study is the small cohort size,
and it could be argued that even the combined 40 animals may
have not been sufficient to reveal the few animals which may
present with clinical symptoms. However, at a face value, if
macaque susceptibility was similar to that in humans, we should
have observed symptoms in at least 8 animals. The fact that we
used a substantial number of old animals, as well as animals with
drastically reduced adaptive cellular immunity (which in humans
and mice serves as strong predictor of susceptibility), allows us to
conclude that sensitivity of old macaques to WNV is low, certainly
lower than in mice (note, that the same WNV stock, lethal for most
old B6 mice at 1,000 pfu - corresponding to ,5610
4/kg - in our
mouse studies [9] was used in the present macaque study without
producing any clinical symptoms in monkeys) or humans.
Therefore, we conclude that macaques are unlikely to provide a
good model of age-related susceptibility to WNV, but may be
useful to elucidate mechanisms by which they rapidly resolve
WNV infection. In that regard, it should be noted that the various
approaches employed to elicit a clinical response, including
increased viral inoculum and priming with SGE, resulted in
either a more rapid resolution of viral RNA loads, or a complete
lack thereof, likely reflecting robust innate responses. Indeed, even
when animals exhibited viral genomes in both the blood and urine,
multiple attempts to culture infectious virus from urine, whole
blood, or plasma were unsuccessful. Attempts to enrich for the
virus from urine using co-cultivation in Vero cells were also
unsuccessful (not shown). This could potentially occur due to
natural antibody, complement neutralization (no preliminary
evidence was found for either), or by other mechanisms, whose
investigation is outside of the scope of this study. Paradoxically, we
have noted the longest viral persistence (albeit coupled with the
inability to culture infectious virus) in Cohort 1 animals, which
received the relatively lowest viral dose in the absence of SGE. We
speculate that this is due to the fact that in all other cohorts either
higher viral doses or the presence of SGE probably stimulated
stronger innate immune response, which promptly neutralized the
Figure 5. Analysis of cell cycle markers suggests an age associated delay in CD4+ proliferation. We used multi-parameter flow cytometry
to evaluate the proliferation kinetics of CD4+ cells in each of our cohorts. The dark lines illustrate the two old animals whereas the lighter lines
illustrate the two adult animals. The cell cycling is normalized to the baseline cycling recorded during this challenge for each animal, setting this to
0%. This illustration reveals that post WNV infection CD4+ cell cycling decreased followed by a marked increase on days 7, 10 and 14 which then
wanes. Of particular interest is the age associated shift in kinetics both older animals (dashed lines) had a slower increase in CD4+ cycling than the
adult animals (solid lines) and a prolonged phase prior to returning to a steady state post infection.
doi:10.1371/journal.pone.0015514.g005
Figure 4. Aged and adult macaques produce robust anti WNV IgM and IgG response. Panels 1–8 illustrate WNV specific antibody
production from Cohort 1 begins about day 10 peaking by day 21 and maintaining in most animals out well past day 45. HI (hemaglutination) assay
on the left vertical axis, and IgG and IgM specific Elisa assays are on the right vertical axis reported P/N values (positive over negative), the assay limit
of detection is P/N.2 is positive.
doi:10.1371/journal.pone.0015514.g004
Aged Monkeys Resist WNV Challenge
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in animals immunized in the presence of SGE, than in those not
receiving the extract (Figure 4).
The humoral immune response in Cohort 1, which exhibited
the most pronounced and longest viremia and WNV shedding,
revealed a similar IgM response to Roehrig’s paper on persistence
of IgM response in humans [21]. The human IgM response
usually coincides with the onset of clinical symptoms. Normally
this response declines over 2–3 months but we saw persistence of
these responses, sometimes lasting up to day 230, and suggesting
persistence of antigen. Also of interest was the presence of a
secondary IgM wave of response. This data is compelling in light
of results showing persistent WNV infection in hamsters [8] and
findings of persistent IgM and non-culturable viral genomes shed
in human urine [22]collectively suggesting that WNV may not
behave as a typical acute pathogen. Whether the prolonged anti-
WNV Ab response is needed to control persistent virus in
macaques or whether it merely represents a bystander phenom-
enon, with other mechanisms keeping the virus at bay, remains to
be elucidated. Of note, we did not observe differences between
adult and old animals in the intensity of Ab responses. This could
be interpreted to mean that in monkeys either the entire immune
system or perhaps just B cells do not undergo the process of age-
related deterioration seen in rodents and humans. We do not
believe this to be correct, because B and T cells in RM readily
exhibit the landmarks of immune senescence, including conversion
into memory cells [23], naı ¨ve cell reduction [23,24]and reduced
T-cell effector function and Ab production in response to
vaccination [25] and references therein]. Consistent with this,
we observed a delay in T-cell proliferation in response to WNV
infection, similar to the observations made in rodents [9] Rather,
we believe it likely that the interaction between the specific virus or
category of viruses and/or the high viral dose used in all animals
may have circumvented any age-related differences and had
produced a robust humoral response. As mentioned above, we do
not believe that adaptive responses were necessary, because robust
limiting of viral loads in SGE-immunized RM caused full
protection, which was accompanied by low Ab titers in these
same animals.
Our primary hypothesis was that including animals of
significantly advanced age and increasing dosage or including
intravenous route of infection would elicit neurological symptoms.
Instead both of these parameters correlated to rapid resolution of
circulating viral RNA. Our second hypothesis, that more severe
WNV disease can be induced by priming animals with mosquito
SGE (as would occur in WNV-endemic areas) and remarkably,
our third hypothesis, that deficient antiviral response in CD8-
depleted and thymectomized CM, will also increase severity of
WNV disease, were also proven incorrect. It was recently [17]
shown that increased mortality and reduced time to death occur
when mice are pre-exposed to mosquito feeding. To mimic this
paradigm we administered SGE in micro-subcutaneous injections
but found instead enhanced protection, as evidence by the
decreased viral load (including 20/20 aged and immunocompro-
mised animals). This raises interesting questions on protection vs.
exacerbation of the vector-borne disease. Our current study
provides suggestive evidence of a heightened innate immune
response including elevation of total monocyte counts (i.v.
infection, not shown) and prolonged eosinophilia, in animals
primed with SGE, however, these leads will require additional
work to establish their importance. Indeed, understanding the
mechanisms of protection at play in old and immunocompromised
macaques against WNV could provide new therapeutic targets
and strategies against this and other similar viral infection in the
old age.
Materials and Methods
Animals
Colony bred and wild caught male and female Rhesus
macaques (Macaca Mulatta) (RM) and Cynomolgus macaques
(Macaca Fascicularis) (CM) were maintained according to federal,
state and local guidelines. All RM were of Indian origin, whereas
CM were from China and Mauritius. Nonhuman primate studies
were performed in biosafety level 3 biocontainment at the Oregon
national Primate Research Center (ONPRC) and the protocol was
approved by the Oregon Health Sciences’ ONPRC Animal Care
and use Committee and carried out in strict accordance with the
recommendations of the National Institutes of Health’s (NIH)
‘‘Guide for the Care and use of Laboratory Animals’’ and the U.S.
Animal Welfare Act. The ONPRC is an American Association for
Accreditation of Laboratory Animal Care (AAALAC)-accredited,
NIH-supported non-human primate (NHP) research facility and
has an approved Assurance (#3304-01) for the care and use of
animals on file with the Office for Protection from Research Risks
at NIH. Animals were acclimatized for 21 days prior to infection.
Animals were monitored (pre- and post-infection) and fed
commercial monkey chow, treats and fruit twice daily. Environ-
mental enrichment consisted of commercial toys and visual
stimulation. All surgical and invasive clinical procedures were
conducted by trained personnel under the supervision of
veterinarians in dedicated surgical facilities using aseptic tech-
niques and comprehensive physiologic monitoring. Ketamine HCl
was used to induce anesthesia for all routine non-invasive clinical
procedures associated with the study protocol such as blood
sampling, bronchoalveolar lavage, drug administration and
clinical examinations or treatment. TelazolH was used to induce
anesthesia for peripheral lymph node biopsy. All animals were
provided analgesia during and after potentially painful procedures.
Animals were pre-screened to be free from tumors, signs of clinical
Figure 6. Immunodeficient animals – CD8 depleted animals
survive WNV infection. CD8+ Tcells from previously thymectomized
and CD8 depleted animals were enumerated from total PBMC using
multi-parameter flow cytometry prior to WNV infection. Twelve months
prior to infection animals were thymectomized (N=4), thymectomized
and CD8 depleted (N=4), only CD8 depleted (N=3) or controls (N=4)
(dark filled circles) Light circles illustrate thymectomized animals, dark
circles illustrate control (sham operated) animals and light filled circles
represent CD8 depletion.
doi:10.1371/journal.pone.0015514.g006
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flaviviruses (SLEV, JEV. TBE, YFV, DEN1-4). Cohort description
(25 RM and 15 CM) is shown in Table 1.
Infection and sampling of macaques
The WNV viral stock was derived from the second-round
passage of a snowy owl liver isolate (WNV 385-99) grown in C6/
36 insect cells, followed by sucrose gradient purification. The same
viral stock was used for all experimental infections, and dose
verified by plaque assay using the material left over after infection.
Doses and routes are described in Table 1. Mosquito salivary
gland extract (SGE), one (1) SGE was defined as the sonicate from
one individual mosquito’s pair of salivary glands. Animals were
sampled by lymph node biopsy, bronchio-alveolar lavage,
cerebrospinal fluid (CSF), urine (via cytesis) and blood for baseline
measurements prior to infection or mosquito salivary gland
priming and sampled post infection at indicated intervals from
indicated tissues.
Telemetry
Telemetry was used to acquire in-vivo temperature & activity
every 2-59, 24 h/day; it consisted of implantable TA-D70
transmitters and receivers (Data Sciences International, St. Paul,
MN), data matrix, PCI card, and VitalView software (Mini Mitter,
Bend, OR). Data were processed using MSExcel, and OriginLab
graphing software was used to provide visual representations of
change over time.
Reverse Transcription quantitative PCR (qPCR)
One step RT-PCR kit [master mix and RT; Applied Biosystems
(Taqman, One-step RT-PCR master mix reagents, cat #
4309169)] was used to amplify a 100 bp segment of the WNV
genome within the NS3 region [26] [primers: Fwd: 59-GCACT-
GAGA GGACTGCCCAT Rev: 5 -TGGGTGAGGGTAGCAT-
GACA Probe: 5 -6FAM-TACCAG ACATCCGCAGTGCC-
CAGA-T-TAMRA] were used for 40 cycles of: 48uC, 309;
95uC, 10’; 95uC, 1599R60uC1 9. Assay limit of detection was set at
1000 genome copies/mg RNA.
Flow Cytometry
PBMCs were stained for phenotype and proliferative response
as in [23,24] using mAb against human CD3, CD4, CD8?
(Beckman Coulter, clone 2ST8.5H7),CD20, and HLA-DR, (BD,
eBioscience and BioLegend). Following washing, fixing, permea-
bilization, and overnight DNA digestion (0.28 mg bovine
pancreas-derived DNase, Sigma–Aldrich), intracellular staining
was performed using anti-Ki-67-FITC (Becton Dickinson, clone
B56) for 30’. At least 3610
5 events were acquired using the LSR-II
cytometer (Becton Dickinson) equipped with DiVa software and
the FCS3.0 file system, and analyzed using FlowJo 8.2 (TreeStar)
software.
Hemaggluination-inhibition (HI) assays
HI antibodies to WNV antigen were measured as previously
described [18]. Plasma was screened at 1:10 against WNV and
SLEV antigens. Positive samples were subsequently titrated using
serial 2-fold dilutions.
Anti-WNV IgG and IgM ELISA
The CDC protocol for IgG and IgM antibody capture enzyme-
linked immunosorbent assay (MAC-ELISA) was followed [27].
Briefly, we used duplicate samples with positive and negative
controls. An average absorbance of each was determined at
450 nm. The optical density of the experimental plasma was
divided by that of the negative control to determine the P/N ratio.
Test interpretation was as follows: P/N,2=negative result, P/
N=2 to 3=equivocal result, P/N.3=positive.
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